← Product Code [GAM](/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM) · K061796 # HEPATOSTAT SET, MODEL 760X (K061796) _Vygon Corp. · GAM · Nov 2, 2006 · General, Plastic Surgery · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM/K061796 ## Device Facts - **Applicant:** Vygon Corp. - **Product Code:** [GAM](/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM.md) - **Decision Date:** Nov 2, 2006 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 878.4493 - **Device Class:** Class 2 - **Review Panel:** General, Plastic Surgery - **Attributes:** Therapeutic ## Intended Use Hepatostat Set is a compression system acting as a tourniquet on the hepatic tissue. It is intended to reduce the risk of bleeding and to achieve hemostasis in hepatic resections (from large to small superficial hepatectomy). It can also be used for traumatic liver injuries. ## Device Story Hepatostat Set is an absorbable compression system used during hepatic surgery. It consists of four pre-perforated absorbable strips sutured together with polyfilament ligatures. The device is applied by a surgeon to the liver tissue, acting as a tourniquet to compress the tissue and achieve hemostasis during resections or traumatic injury repair. The strips and sutures are composed of copolymers that degrade via hydrolysis into glycolic and lactic acid, which are metabolized and absorbed by the body. The device provides mechanical compression to prevent bleeding; it does not require removal as it is fully absorbed by the body over 60-90 days. ## Clinical Evidence No clinical data. Evidence consists of bench testing, including biocompatibility testing per ISO 10993-1 (implantation testing at 3, 6, 12, and 15 months) and sterility testing (SAL 10^-6). ## Technological Characteristics Absorbable compression strips and polyfilament sutures made of copolymers that degrade via hydrolysis into glycolic and lactic acid. Biocompatibility per ISO 10993-1. Sterilization ensures SAL 10^-6. Mechanical tourniquet principle of operation. ## Regulatory Identification An absorbable poly(glycolide/l-lactide) surgical suture (PGL suture) is an absorbable sterile, flexible strand as prepared and synthesized from homopolymers of glycolide and copolymers made from 90 percent glycolide and 10 percent l-lactide, and is indicated for use in soft tissue approximation. A PGL suture meets United States Pharmacopeia (U.S.P.) requirements as described in the U.S.P. “Monograph for Absorbable Surgical Sutures;” it may be monofilament or multifilament (braided) in form; it may be uncoated or coated; and it may be undyed or dyed with an FDA-approved color additive. Also, the suture may be provided with or without a standard needle attached. ## Special Controls *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document. ## Predicate Devices - Mar-Med Liver Strap ([K924223](/device/K924223.md)) - Vicryl Synthetic Absorbable Surgical Suture ([K033746](/device/K033746.md)) - Safil Synthetic Absorbable Surgical Suture ([K031286](/device/K031286.md)) - MonoSyn Synthetic Absorbable Surgical Suture ([K011375](/device/K011375.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Kα61796 page i/2 ## VYGON CORPORATION 2495 General Armistead Avenue Norristown, PA 19403-3685 > (800) 544-4907 (610) 630-3350 Fax (610) 630-3835 ## 510K Premarket Notification Submission Summary of Safety and Efficacy Date of Preparation: September 22, 2006 NOV - 2 2006 Applicant: Vygon Corporation 2495 General Armistead Ave. Norristown, PA 19403 878.4493 + 878. 4800 Mar-Med Liver Strap (K924223) through the liver with a tubular needle. Contact Individual: Courtney Smith, Regulatory Affairs Manager 610-539-9300 Ext. 110 Trade Name: Common Name: Product Code: Classification Name: Classification: Class II Predicate Device Name: Device Description: Vicryl Synthetic Absorbable Surgical Suture (K033746) The Hepatostat Set is an absorbable compression device which was developed for the purpose of hepatic resection, large or small, without any significant bleeding. It consists of four pre-perforated absorbable strips which are sutured together with Safil polyfilament ligatures introduced Synthetic Absorbable Surgical Suture & Surgical Clamp Safil Synthetic Absorbable Surgical Suture (K031286) MonoSyn Synthetic Absorbable Surgical Suture (K011375) Intended Use: Hepatostat Set is a compression system acting as a tourniquet on the hepatic tissue. It is intended to reduce the risk of bleeding and to achieve hemostasis in hepatic resections (from large to small superficial hepatectomy). It can also be used for traumatic liver injuries. Vicon Hepatostat Set AbSorbable GAM Liver Clamp Name: **Name:** Regulation Number: **Product Code:** **Classification Name** C **Predicate Device Names** {1}------------------------------------------------ K061796 Page 42 Technology Characteristics: The Absorbable strips and Safile sutures are broken down by bydrolysis, both copolymers degrade into glycolic and lactic acid which are subsequently metabolized and absorbed by the body. Liver hemostasis is fairly rapid (approximately 15 days) and is not impeded by the reabsorption of the strips and sutures. Complete absorption of the sutures occurs between 60 and 60 days. ## Summary of Design Control Activities: Biocompatibility testing of the material in accordance with ISO 10993-1, including implantation testing at 3, 6, 12 and 15 months demonstrates performance and biocompatibility of the device. In vitro testing demonstrates that the device performance. Sterility testing ensures a sterility assurance level of 10-6. Conclusion: Biocompatibility and implant testing, performance testing and risk assessment demonstrate that the Hepatostat Set is safe and effective to use, when used in accordance with the supplied instructions for use. {2}------------------------------------------------ Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a circular seal with the words "DEPARTMENT OF HEALTH AND HUMAN SERVICES - USA" arranged around the perimeter. Inside the circle is an abstract symbol resembling an eagle or bird in flight, composed of three curved lines. The logo is presented in black and white. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 Vygon Corporation % Regulatory Affairs Associates, LLC Mr. Stephen Goldner 30833 Northwestern Highway Suite 121 Farmington Hills, Michigan 48334 NOV - 2 2006 Re: K061796 Trade/Device Name: Hepatostat Regulation Number: 21 CFR 878.4493 Regulation Name: Absorbable poly(glycolide/L-lactide) surgical suture Regulatory Class: II Product Code: GAM, GDJ Dated: September 30, 2006 Received: October 3, 2006 Dear Mr. Goldner: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration, If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. {3}------------------------------------------------ Page 2 – Mr. Stephen Goldner This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, for Mark N. Melkerson Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indications for Use 510(k) Number (if known): K061796 Device Name: Hepatostat Indications For Use: Hepatostat Set is a compression system acting as a tourniquet on the hepatic tissue. It is intended to reduce the risk of bleeding and to achieve hemostasis in hepatic resections (from large to small superficial hepatectomy). It can also be used for traumatic liver injuries. Prescription Use X X AND/OR Over-The-Counter Use (Part 21 CFR 801 Subpart D) (21 CFR 807 Subpart C) (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) R. Rmz Page 1 of ____________________________________________________________________________________________________________________________________________________________________ Division of General Restorative. and Neurological Devices 510(k) Number L061796 --- **Source:** [https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM/K061796](https://fda.innolitics.com/submissions/SU/subpart-e%E2%80%94surgical-devices/GAM/K061796) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com